: City-based drug-maker Laurus Labs Ltd Monday received final approval from the United States Food and Drug Administration (US FDA) for hydroxychloroquine tablets 200 mg meant to treat a certain type of malaria.
The tablet is also used, usually with other medications, to treat certain auto-immune diseases (lupus, rheumatoid arthritis), a press release said here.
Hydroxychloroquine is therapeutically equivalent to plaquenil tablets 200 mg of Concordia Pharmaceuticals, Inc, the release said.
Also, Laurus Labs received a tentative approval for an ANDA (abbreviated new drug application) for Abacavir, Dolutegravir and Lamivudine tablets from the US FDA, it said.
The products would be commercialised from Laurus's manufacturing site in Visakhapatnam, it added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app